Please assess the completion status of the following clinical trial:

Trial Title: ADV-TK Improves Outcome of Recurrent High-Grade Glioma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed WHO grades 3 to 4 malignant glioma~* Diagnosed recurrence or progression by clinical or radiological evidence~* Fit for intraarterial infusion and intravenous chemotherapy~* Adequate hepatic, renal, and hematologic function.~* Legal age ≥18 years~* Life expectancy ≥12 weeks~* Eastern Cooperative Oncology Group performance (ECOG) ≥2~* Chemotherapy completion ≥4 weeks prior and recovery from drug induced toxicities.~Exclusion Criteria:~* Active pregnancy~* Prior gene therapy~* Second primary tumor~* Gravidity, lactation, hypersensitivity to antiviral drugs, immunologic deficit, active uncontrolled infections~* Requiring treatment with warfarin or any other anticoagulants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ADV-TK/GCV (Type: EXPERIMENTAL): ADV-TK was administered via intraarterial cerebral infusion. Systemic GCV therapy was delivered at a dose of 5mg/kg intravenous, every 12 h at 36 hours after ADV-TK therapy.
- Control group (Type: ACTIVE_COMPARATOR): Patients received surgery or systemic chemotherapy or palliative care.

Based on this trial design, predict the completion outcome and termination type (if applicable).